KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Debt (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Total Debt for 13 consecutive years, with $68.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Total Debt changed N/A year-over-year to $68.8 million, compared with a TTM value of $68.8 million through Jun 2025, changed N/A, and an annual FY2024 reading of $68.7 million, changed N/A over the prior year.
  • Total Debt was $68.8 million for Q2 2025 at Travere Therapeutics, roughly flat from $68.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $68.8 million in Q2 2025 and bottomed at $6.9 million in Q1 2023.
  • Average Total Debt over 5 years is $29.6 million, with a median of $7.4 million recorded in 2021.
  • The sharpest move saw Total Debt plummeted 57.47% in 2021, then decreased 5.41% in 2022.
  • Year by year, Total Debt stood at $7.4 million in 2021, then fell by 5.41% to $7.0 million in 2022, then fell by 1.43% to $6.9 million in 2023, then skyrocketed by 895.33% to $68.7 million in 2024, then increased by 0.23% to $68.8 million in 2025.
  • Business Quant data shows Total Debt for TVTX at $68.8 million in Q2 2025, $68.8 million in Q1 2025, and $68.7 million in Q4 2024.